ASO Author Reflections: Prognostic Value of Subgrading G2 Pancreatic Neuroendocrine Tumors as 2A versus 2B

Affiliations

¹ Department of Pathology, Koç University, Koç University Hospital, Istanbul, Türkiye.
² Department of Pathology, Marmara University, Istanbul, Türkiye.
³ Department of Pathology, Memorial Sisli Hospital, Istanbul, Türkiye.
⁴ Department of Pathology, St. Marianna University, Kawasaki, Kanagawa, Japan.
⁵ Department of Pathology, Hacettepe University, Ankara, Türkiye.
⁶ Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁷ Department of Pathology, Emory University, Atlanta, GA, USA.
⁸ Department of Surgery, Emory University, Atlanta, GA, USA.
⁹ Department of Pathology, Piedmont Hospital, Atlanta, GA, USA.
¹⁰ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Department of Diagnostics and Public Health, Section of Pathology and ARC-Net Research Centre, University of Verona, Verona, Italy.
¹² Department of Pathology, Koç University, Koç University Hospital, Istanbul, Türkiye. adsay.volkan@gmail.com.

Ozgur Can Eren et al. Ann Surg Oncol. 2024 Oct.

. 2024 Oct;31(10):7068-7069.

doi: 10.1245/s10434-024-15728-5. Epub 2024 Jul 11.

¹ Department of Pathology, Koç University, Koç University Hospital, Istanbul, Türkiye.
² Department of Pathology, Marmara University, Istanbul, Türkiye.
³ Department of Pathology, Memorial Sisli Hospital, Istanbul, Türkiye.
⁴ Department of Pathology, St. Marianna University, Kawasaki, Kanagawa, Japan.
⁵ Department of Pathology, Hacettepe University, Ankara, Türkiye.
⁶ Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁷ Department of Pathology, Emory University, Atlanta, GA, USA.
⁸ Department of Surgery, Emory University, Atlanta, GA, USA.
⁹ Department of Pathology, Piedmont Hospital, Atlanta, GA, USA.
¹⁰ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Department of Diagnostics and Public Health, Section of Pathology and ARC-Net Research Centre, University of Verona, Verona, Italy.
¹² Department of Pathology, Koç University, Koç University Hospital, Istanbul, Türkiye. adsay.volkan@gmail.com.

No abstract available

References

1. Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. BMC Cancer. 2023;23(1):908. https://doi.org/10.1186/s12885-023-11287-2.PMID:37752423;PMCID:PMC10523723 . - DOI - PubMed - PMC
1. Müller C, Kreissl MC, Klose S, Krause A, Keitel V, Venerito M. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. Medicine Balt. 2022;101(4):e28610. https://doi.org/10.1097/MD.0000000000028610.PMID:35089197;PMCID:PMC8797514 . - DOI
1. Eren OC, Bagci P, Balci S, et al. Subgrading of G2 pancreatic neuroendocrine tumors as 2A (Ki67 3% to < 10%) versus 2B (10% to ≤ 20%) identifies behaviorally distinct subsets in keeping with the evolving management protocols. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15632-y . - DOI - PubMed